Prosecution Insights
Prosecution Insights
12 pending office actions • 4 clients • 12 examiners • 11 art units • 0 of 12 (0%) have an AI response strategy ready • 33 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 7 (58%) |
| §112 only | 1 (8%) |
| No statute on record | 4 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MELCHIOR, JAMES RYLAND | 1 | 61.0% | +44.6% |
| SALMON, KATHERINE D | 1 | 42.6% | +38.0% |
| STOICA, ELLY GERALD | 1 | 66.5% | +22.9% |
| PARKIN, JEFFREY S | 1 | 63.5% | +21.4% |
| BRISTOL, LYNN ANNE | 1 | 63.7% | +39.7% |
| CORDAS, EMILY ANN | 1 | 50.6% | +58.5% |
| LIN, JERRY | 1 | 72.3% | +15.2% |
| YAO, LEI | 1 | 60.0% | +65.6% |
| REDDIG, PETER J | 1 | 58.0% | +40.0% |
| GAO, ASHLEY HARTMAN | 1 | 59.8% | +38.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18150136 | Neoepitope vaccine and immune stimulant combinations and methods | BRISTOL, LYNN ANNE | 111d overdue |
| 18339106 | USE OF CIRCULATING CELL-FREE RNA FOR DIAGNOSIS AND/OR MONITORING CANCER | SALMON, KATHERINE D | 96d overdue |
| 18005332 | COVID-19 Mucosal Antibody Assay | PARKIN, JEFFREY S | 30d overdue |
| 17115360 | Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection | REDDIG, PETER J | 2d overdue |
| 16961026 | Fusion Protein Extensions | GAO, ASHLEY HARTMAN | 5d |
| 18325860 | METHOD OF TREATMENT OF A TUMOR WITH IL-8 ANTIBODY | STOICA, ELLY GERALD | 6d |
| 17767615 | Detecting Homologous Recombination Deficiencies (HRD) in Clinical Samples | LIN, JERRY | 16d |
| 18258925 | Fc-Receptor CAR Constructs and Cells | MELCHIOR, JAMES RYLAND | 54d |
| Client (Assignee) | Pending OAs |
|---|---|
| ImmunityBio | 5 |
| NantWorks | 5 |
| Liquid Genomics | 1 |
| Five3 Genomics | 1 |
| Art Unit | Apps |
|---|---|
| 1632 | 2 |
| 1644 | 1 |
| 1682 | 1 |
| 1647 | 1 |
| 1671 | 1 |
| 1643 | 1 |
| 1685 | 1 |
| 1642 | 1 |
| 1646 | 1 |
| 1678 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18258925 | Fc-Receptor CAR Constructs and Cells | Immunitybio, Inc. | MELCHIOR, JAMES RYLAND | 1644 | §103 | Non-Final OA | 54d | Pending | Jun 22, 2023 |
| 18339106 | USE OF CIRCULATING CELL-FREE RNA FOR DIAGNOSIS AND/OR MONITORING CANCER | Liquid Genomics, Inc. | SALMON, KATHERINE D | 1682 | §103 | Non-Final OA | 96d overdue | Pending | Jun 21, 2023 |
| 18325860 | METHOD OF TREATMENT OF A TUMOR WITH IL-8 ANTIBODY | Nantbio, Inc. | STOICA, ELLY GERALD | 1647 | Other | Non-Final OA | 6d | Pending | May 30, 2023 |
| 18005332 | COVID-19 Mucosal Antibody Assay | Nantcell, Inc. | PARKIN, JEFFREY S | 1671 | §112 | Non-Final OA | 30d overdue | Pending | Jan 12, 2023 |
| 18150136 | Neoepitope vaccine and immune stimulant combinations and methods | Nantcell, Inc. | BRISTOL, LYNN ANNE | 1643 | §103 | Non-Final OA | 111d overdue | Pending | Jan 04, 2023 |
| 17795735 | Elimination of BCMA-positive malignancies by CAR expressing NK cells | Immunitybio, Inc. | CORDAS, EMILY ANN | 1632 | §103 | Final Rejection | 60d | Pending | Jul 27, 2022 |
| 17767615 | Detecting Homologous Recombination Deficiencies (HRD) in Clinical Samples | Immunitybio, Inc. | LIN, JERRY | 1685 | §103 | Non-Final OA | 16d | Pending | Apr 08, 2022 |
| 17294891 | Methods of Making Therapeutic T Lymphocytes | Nantomics, LLC | YAO, LEI | 1642 | §103 | Final Rejection | 68d | Pending | May 18, 2021 |
| 17115360 | Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection | Immunitybio, Inc. | REDDIG, PETER J | 1646 | Other | Non-Final OA | 2d overdue | Pending | Dec 08, 2020 |
| 16961026 | Fusion Protein Extensions | Nantbio, Inc. | GAO, ASHLEY HARTMAN | 1678 | §103 | Final Rejection | 5d | Pending | Oct 15, 2020 |
| 16985090 | Artificial Target Cells for in-vitro CAR Cytotoxicity and ADCC validation | Immunitybio, Inc. | DHAR, MATASHA | 1632 | Other | Non-Final OA | 743d overdue | Pending | Aug 04, 2020 |
| 16222798 | Systems and Methods For RNA Analysis In Functional Confirmation Of Cancer Mutations | Five3 Genomics, LLC | ZEMAN, MARY K | 1686 | Other | Non-Final OA | 77d overdue | Pending | Dec 17, 2018 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial